Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Login Sign up free
Home Screener Maps Charts News Groups Insider Futures Forex Crypto Portfolio Calendar
Pricing

New feature:   Introducing the Finviz Matrix

Learn More
Market News Market Pulse Stocks News ETF News Crypto News

Tenax Therapeutics, Inc.

Contributing Author

Recent Articles by Tenax Therapeutics, Inc.

Sep-01
Tenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference TENX GlobeNewswire
Aug-29
Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026 TENX GlobeNewswire
Aug-10
Tenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF TENX -89.77% GlobeNewswire
Jul-31
Tenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update TENX -9.27% GlobeNewswire
Jul-02
Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) TENX +16.33% TENX +5.17% GlobeNewswire
Jul-02
Tenax Therapeutics Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 2026 TENX +16.33% GlobeNewswire
May-12
Tenax Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update TENX GlobeNewswire
May-08
Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) TENX GlobeNewswire
May-04
Tenax Therapeutics Appoints Timothy Healey, MBA as Chief Commercial Officer TENX GlobeNewswire
Apr-22
Tenax Therapeutics Appoints Thomas R. Staab, II as Chief Financial Officer TENX GlobeNewswire
Mar-10
Tenax Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update TENX +31.67% GlobeNewswire
Mar-03
Tenax Therapeutics to Participate in the 2026 Leerink Partners Global Healthcare Conference TENX GlobeNewswire
Feb-04
Tenax Therapeutics to Participate in the Guggenheim Emerging Outlook Biotech Summit 2026 TENX GlobeNewswire
Dec-17
Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment TENX +5.65% GlobeNewswire
Nov-25
Tenax Therapeutics to Participate in Upcoming Investor Conferences TENX GlobeNewswire
Nov-12
Tenax Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update TENX GlobeNewswire
Nov-06
Tenax Therapeutics to Host Virtual KOL Call to Discuss TNX-103 (Oral Levosimendan) for the Treatment of PH-HFpEF TENX GlobeNewswire
Nov-03
Tenax Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference TENX GlobeNewswire
Sep-16
Tenax Therapeutics Announces European Patent Office Intention to Grant Patent Covering Use of Levosimendan in PH-HFpEF TENX GlobeNewswire
Aug-28
Tenax Therapeutics to Participate in the Cantor Global Healthcare Conference 2025 TENX GlobeNewswire
Aug-13
Tenax Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update TENX GlobeNewswire
May-14
Tenax Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update TENX GlobeNewswire
Affiliate • Advertise • API and Exports • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)